MAGLUMI非竞争性血管紧张素I化学发光免疫法检测血浆肾素活性的性能评价
该研究评估了MAGLUMI血管紧张素I化学发光免疫法测定血浆肾素活性(PRA)的分析性能,并与LC-MS/MS进行比较。结果显示该方法精密度、线性、检测限和参考区间验证均表现良好,与LC-MS/MS一致性优秀,适用于临床检测PRA。
要点
- MAGLUMI血管紧张素I法精密度高,重复性1.5%~1.85%,室内不精密度1.9%~2.5%。
- 与LC-MS/MS一致性优秀:血管紧张素I r=0.987,PRA r=0.973(p<0.001)。
- 线性范围0.10~24.0 ng/mL,LoB 0.03、LoD 0.07、LoQ 0.10 ng/mL。
核心结论
- MAGLUMI血管紧张素I化学发光免疫法灵敏可靠,分析性能稳健,与LC-MS/MS高度一致,适用于检测血浆肾素活性。
研究设计与样本
- 评估MAGLUMI血管紧张素I化学发光免疫法的精密度、线性、空白限、检测限、定量限、干扰、交叉反应和参考区间。
- 与LC-MS/MS比较使用54例样本,临床因素影响评估使用181例样本,参考区间验证使用40例健康个体血浆样本。
主要发现
- 三个不同浓度混合样本的重复性分别为1.5%、1.85%、1.6%,室内不精密度分别为2.0%、2.5%、1.9%。
- 线性范围为[0.10, 24.0] ng/mL;LoB、LoD、LoQ分别为0.03 ng/mL、0.07 ng/mL、0.10 ng/mL。
- 干扰和交叉反应符合可接受标准(交叉反应<±10%)。
- 参考区间验证显示,40例健康个体血浆样本中仰卧位和立位落在已建立区间外的比例均<10%。
- 与LC-MS/MS比较:血管紧张素I斜率=1.076,截距=0.109 ng/mL/h,r=0.987,p<0.001;血浆肾素活性斜率=1.131,截距=-0.386 ng/mL/h,r=0.973,p<0.001。
关键数值与推荐
- 重复性:1.5%、1.85%、1.6%(三个不同浓度混合样本)。
- 室内不精密度:2.0%、2.5%、1.9%(对应上述三个浓度)。
- 线性范围:[0.10, 24.0] ng/mL。
- LoB=0.03 ng/mL,LoD=0.07 ng/mL,LoQ=0.10 ng/mL。
- 交叉反应可接受标准:<±10%。
临床怎么用
- 该化学发光免疫法可用于临床检测血浆肾素活性,结果与LC-MS/MS一致性高,可支持肾素-血管紧张素-醛固酮系统功能评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Plasma renin activity (PRA) measures the rate of renin converting angiotensinogen to angiotensin I in circulation and reflects the function of renin-angiotensin-aldosterone system (RAAS). The study aimed to demonstrate the performance of the MAGLUMI Angiotensin I assay for the measurement of PRA. METHODS: The MAGLUMI Angiotensin I assay was evaluated for precision, linearity, limit of blank (LoB), limit of detection (LoD), limit of quantification (LoQ), interferences, cross-reactivity and reference intervals. It was compared to liquid chromatography tandem mass spectrometry (LC-MS/MS) using 54 samples, and impact of clinical factors was assessed in 181 samples. RESULTS: The assay demonstrated repeatability of 1.5 %, 1.85%, and 1.6 % across three different pool concentrations, with corresponding within-laboratory imprecision values of 2.0 %, 2.5%, and 1.9 %. The linear range was [0.10, 24.0] ng/mL. The LoB, the LoD, and the LoQ were 0.03 ng/mL, 0.07 ng/mL, and 0.10 ng/mL, respectively. The interferences and cross-reactivity met the criterion for acceptable cross-reactivity (CR) with <±10 %. Reference interval validation shows <10 % of a total of 40 healthy individuals' plasma samples falling outside the established interval for standing and lying position. The MAGLUMI assay showed excellent agreement with LC-MS/MS for both angiotensin I (slope=1.076, intercept=0.109 ng/mL/h, r=0.987, p<0.001) and plasma renin activity (slope=1.131, intercept=-0.386 ng/mL/h, r=0.973, p<0.001). CONCLUSIONS: The MAGLUMI Angiotensin I chemiluminescence immunoassay is a sensitive and reliable commercial kit for detecting plasma renin activity. The assay exhibited robust analytical performance and strong agreement with LC-MS/MS.
引用
- Wu L, Zhang B, Zhang Y, et al. Evaluation of the MAGLUMI non-competitive angiotensin I chemiluminescence immunoassay for measuring renin activity in human plasma. Clin Chem Lab Med. 2026. PMID: 41492819. doi:10.1515/cclm-2025-1361
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。